Clovis Oncology Inc

News 09/19/18, 22:23

A Colorado-based biopharmaceutical company has been penalized more than $20 million for misleading investors about the efficacy of a lung cancer drug under development before raising $300 million in a public stock offering.The U.S. Securities and Exchange Commission brought the complaint against Clovis Oncology Inc., of Boulder, and two company ...